Eisavi Mahmoud, Mazaheri Elaheh, Rezapour Aziz, Vahedi Sajad, Hadian Marziye, Jafari Abdosaleh
Assistant Professor, Faculty of Economics, Allameh Tabataba'i University, Tehran, Iran.
Department of Medical Library and Information Sciences, Health Information Technology Research Center, Student Research Committee, School of Management and Medical Information Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Int J Prev Med. 2021 May 15;12:39. doi: 10.4103/ijpvm.IJPVM_125_20. eCollection 2021.
Cardiovascular diseases impose a burden of disease and economic burden on society. With regard to different drugs are used to treat cardiovascular disease; these interventions should be economically evaluated and them that the most cost-effective were selected. The aim of this study was to investigate the studies carried on the cost-effectiveness and cost-utility of statin drugs for the treatment of patients with cardiovascular disease between 2004 and 2020. Quality assessment of the articles was examined by Drummond's checklist. Given that the inclusion criteria, 26 articles included in the review. The results of this review showed that many articles related to the economic evaluation of statin drugs adhered international standards for performing economic evaluation studies. All the studies mentioned the source of effectiveness (the second criteria) and alternative options for the comparison (the third criteria). Atorvastatin and rosuvastatin drugs were the main options for the comparison in the studies. Although the results of the studies were different in some aspects, such as the type of modeling, costs items and the study perspective, they reached the same results which the use of statin drugs versus no-drug can decrease cost, cardiovascular events and deaths and increase QALY. The results were nearly different due to study design, time horizon, efficacy, and drug prices.
心血管疾病给社会带来了疾病负担和经济负担。关于用于治疗心血管疾病的不同药物，应对这些干预措施进行经济学评估，并选择最具成本效益的药物。本研究的目的是调查2004年至2020年间关于他汀类药物治疗心血管疾病患者的成本效益和成本效用的研究。文章的质量评估采用了德拉蒙德检查表。根据纳入标准，该综述纳入了26篇文章。该综述的结果表明，许多关于他汀类药物经济学评估的文章符合进行经济学评估研究的国际标准。所有研究都提到了有效性来源（第二个标准）和比较的替代方案（第三个标准）。阿托伐他汀和瑞舒伐他汀药物是研究中比较的主要选择。尽管研究结果在某些方面存在差异，如建模类型、成本项目和研究视角，但它们得出了相同的结果，即使用他汀类药物与不使用药物相比，可以降低成本、心血管事件和死亡，并增加质量调整生命年。由于研究设计、时间范围、疗效和药物价格的不同，结果也几乎不同。
